Troy Wilson currently serves as president and CEO of Kura Oncology. He has served as president and CEO of Wellspring Biosciences and its parent company Araxes Pharma LLC since July 2012 and as president and CEO of Avidity NanoMedicines since November 2012. Previously, Wilson served as the president, CEO and a board member of Intellikine, until its acquisition by Takeda Pharmaceuticals in 2011. He is a member of the board of directors of Kura Oncology, Puma Biotechnology and Zosano Pharma. Wilson holds a law degree from New York University and graduated with a doctorate in bioorganic chemistry and a B.A. in biophysics from the University of California, Berkeley.
Index Ventures made news recently when it announced a new €150 million fund to invest in early-stage, life science companies. With many venture firms scaling back or exiting the business entirely,... Read more »
Sanofi-Aventis and Merck KGaA announced recently they are teaming up to test new cancer drugs in combination, joining a growing trend among drug makers to combine different cancer therapies in early-stage... Read more »